// App-Quantinova.ai

2866 : Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study

Researchers

Presenter

  • Paul Emery

Principal Investigators

  • Peter C. Taylor

  • Michael Weinblatt

  • Yoshiya Tanaka

  • Edward C. Keystone

  • Ernst R. Dow

  • Richard Higgs

  • William L. Macias

  • Guilherme Rocha

  • Terence P. Rooney

  • Douglas E. Schlichting

  • Steven H. Zuckerman

  • Iain B. McInnes

Medical Centers

  • Leeds MSK Biomed/Chapel Allerton Hosp, Leeds, United Kingdom

  • University of Oxford, Oxford, United Kingdom

  • Brigham and Women's Hospital, Brookline, MA

  • The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan

  • University of Toronto, Toronto, ON, Canada

  • Eli Lilly and Company, Indianapolis, IN

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • United Kingdom

  • United States

  • Japan

  • Canada

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved